The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
NPR reports on companies' efforts to develop genetically modified bacteria to treat disease.
The former cofounder of Knome believes that the future of precision medicine lies in our ability to program living things to act as medicines.
The firm recognized revenues in fiscal Q1 2019 of $11.5 million, driven by rapid growth in its NGS products as well as its synthetic biology business.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.
Ohio State University researchers found that a phosphorothioate-modified DNA-crRNA duplex completely blocked the function of Cas12a.
Aside from its core synthetic biology business, the company has expanded into NGS and is looking to move into drug discovery and DNA data storage.
Twist, which went public in October, reported that its revenues doubled this year due to increased sales of its synthetic DNA products and the introduction of NGS products.
CNGB was founded by the Chinese government and BGI to collect genomics technologies and resources, and promote their use by the research community.
Cowen gave the company a rating of Outperform while JP Morgan assigned its shares a Neutral rating.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.